Sulopenem Explained

Sulopenem (CP-70,429) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s but has never been approved for medical use, however it has reached Phase III clinical trials on several occasions and continues to be the subject of ongoing research into potential applications, especially in the treatment of multiple drug resistant urinary tract infections.[1] [2] [3] [4] [5]

In October 2024, the US Food and Drug Administration approved sulopenem etzadroxil with probenecid combination for the treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited alternative oral antibiotic options. The combination was developed by Iterum Therapeutics under the trade name ORLYNVAH™.[6]

See also

Notes and References

  1. Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S . In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic . Antimicrobial Agents and Chemotherapy . 37 . 7 . 1547–1551 . July 1993 . 8363389 . 10.1128/AAC.37.7.1547 . 188011 .
  2. Hamilton-Miller JM . Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem . Pharmacotherapy . 23 . 11 . 1497–1507 . November 2003 . 14620395 . 10.1592/phco.23.14.1497.31937 . 43705118 .
  3. Ednie LM, Appelbaum PC . Antianaerobic activity of sulopenem compared to six other agents . Antimicrobial Agents and Chemotherapy . 53 . 5 . 2163–2170 . May 2009 . 19223615 . 10.1128/AAC.01557-08 . 2681565 .
  4. Bader MS, Loeb M, Leto D, Brooks AA . Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents . Postgraduate Medicine . 132 . 3 . 234–250 . April 2020 . 31608743 . 10.1080/00325481.2019.1680052 . 204545734 .
  5. Veeraraghavan B, Bakthavatchalam YD, Sahni RD . Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections . Infectious Diseases and Therapy . 10 . 4 . 1815–1835 . December 2021 . 34357517 . 10.1007/s40121-021-00509-4 . 8572892 .
  6. Web site: 2024-10-25 . Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections . 2024-10-25 . Iterum Therapeutics plc . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sulopenem".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.